{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:42:16Z","timestamp":1794440536781,"version":"4.9.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The HIV epidemic in China is characterized by significant genetic diversity with multiple circulating recombinant forms (CRFs). The gp120-CD4 interaction, essential for viral cellular entry, exhibits subtype-dependent structural variations that compromise therapeutic efficacy. Although temsavir remains the only FDA-approved adhesion inhibitor, its activity against predominant HIV subtypes in China has not been systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HIV subtyping of 472 clinical samples identified five major strains (B, CRF01_AE, CRF07_BC, CRF08_BC, and CRF55_01B). Recombinant gp140 proteins from these subtypes were expressed, purified, and analyzed via bio-layer interferometry (BLI) to characterize CD4 binding properties. Structural analyses compared hydrogen bonding and interface buried surface areas. Temsavir\u2019s inhibitory efficacy was assessed, and virtual screening of 13,819 compounds combined with BLI validation was performed to identify novel inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Subtype B demonstrated the strongest CD4 binding affinity (KD=79 pM), while CRF55_01B showed the weakest binding (KD=8.76 nM). CRF variants exhibited reduced hydrogen bonding and smaller interface buried surface areas, correlating with diminished binding affinity. Temsavir inhibition was subtype-dependent, achieving 35.7% inhibition for subtype B versus &amp;lt;1.3% for CRF01_AE and CRF55_01B, primarily due to steric hindrance induced by the S375H mutation. Five novel inhibitors targeting CRF55_01B were identified with inhibition rates 19%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study elucidates the molecular mechanisms of HIV-1 adhesion variation and provides specific candidate HIV adhesion inhibitors for prevalent CRF subtypes in China. Subsequent efforts will focus on preclinical validation and structure\u2013activity relationship optimization of these candidates, laying the groundwork for developing personalized therapeutic strategies against region-specific strains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1648546","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:28:36Z","timestamp":1758518916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains"],"prefix":"10.3389","volume":"16","author":[{"given":"Tianyang","family":"Liu","sequence":"first","affiliation":[{"name":"Institute for Hepatology, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]},{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Li","sequence":"additional","affiliation":[{"name":"Institute for Hepatology, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]},{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]},{"name":"Department of Biology, School of Medicine, Institute for Infectious Disease, Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Yang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease","place":["Shenzhen, China"]},{"name":"State Key Discipline of Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute for Hepatology, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]},{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]},{"name":"Department of Basic Medicine, Jiamusi University","place":["Jiamusi, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute for Hepatology, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]},{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute for Hepatology, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]},{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute for Hepatology, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]},{"name":"Institute for Infectious Disease, The Affiliated Hospital of Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease","place":["Shenzhen, China"]},{"name":"State Key Discipline of Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]},{"name":"Department of Infectious Diseases, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Wei","sequence":"additional","affiliation":[{"name":"Institute for Hepatology, Shenzhen Third People\u2019s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0980-9_20","article-title":"Assembly and architecture of HIV","volume":"726","author":"Ganser-Pornillos","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coviro.2021.07.005","article-title":"HIV-1 entry: Duels between Env and host antiviral transmembrane proteins on the surface of virus particles","volume":"50","author":"Murakami","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0005-2736(03)00161-5","article-title":"The HIV Env-mediated fusion reaction","volume":"1614","author":"Gallo","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.11.020","article-title":"HIV-1-envelope trimer transitions from prefusion-closed to CD4-bound-open conformations through an occluded-intermediate state","volume":"23","author":"Lee","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad327","article-title":"Geographic and population distributions of human immunodeficiency virus (HIV)-1 and HIV-2 circulating subtypes: A systematic literature review and meta-analysis (2010-2021)","volume":"228","author":"Williams","year":"2023","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jinf.2012.10.026","article-title":"Implications of HIV diversity for the HIV-1 pandemic","volume":"66","author":"Hemelaar","year":"2013","journal-title":"J Infect"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328354622a","article-title":"The evolving epidemiology of HIV\/AIDS","volume":"26","author":"De Cock","year":"2012","journal-title":"Aids"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2024.252","article-title":"National and regional molecular epidemiology of HIV-1 - China, 2004-2023","volume":"6","author":"Wang","year":"2024","journal-title":"China CDC Wkly"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06639-8","article-title":"Intermediate conformations of CD4-bound HIV-1 Env heterotrimers","volume":"623","author":"Dam","year":"2023","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.09.026","article-title":"HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites","volume":"512","author":"Joshi","year":"2017","journal-title":"Virology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.073","article-title":"Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1\/V2 region or V3 crown deletion","volume":"37","author":"Fu","year":"2019","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-981-16-8702-0_4","article-title":"The genesis and future prospects of small molecule HIV-1 attachment inhibitors","volume":"1366","author":"Wang","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0163822","DOI":"10.1128\/jvi.01638-22","article-title":"Characterization of a novel CD4 mimetic compound YIR-821 against HIV-1 clinical isolates","volume":"97","author":"Matsumoto","year":"2023","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167395","article-title":"Novel bent conformation of CD4 induced by HIV-1 inhibitor indirectly prevents productive viral attachment","volume":"434","author":"Wensel","year":"2022","journal-title":"J Mol Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku360","article-title":"Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes","volume":"70","author":"Fofana","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/v5020595","article-title":"HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition","volume":"5","author":"Ara\u00fajo","year":"2013","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1038\/s41467-023-42500-2","article-title":"Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir","volume":"14","author":"Pr\u00e9vost","year":"2023","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0029","article-title":"Nationwide trends in molecular epidemiology of HIV-1 in China","volume":"32","author":"Li","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0956462414543841","article-title":"Prevalence of HIV-1 subtypes among men who have sex with men in China: a systematic review","volume":"26","author":"Zhang","year":"2015","journal-title":"Int J STD AIDS"},{"key":"B20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jinf.2021.04.021","article-title":"Molecular surveillance of HIV-1 newly diagnosed infections in Shenzhen, China from 2011 to 2018","volume":"83","author":"Zhang","year":"2021","journal-title":"J Infect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.10.014","article-title":"Infecting\u00a0HIV-1 subtype predicts disease progression in women of sub-saharan africa","volume":"13","author":"Venner","year":"2016","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2019.06.002","article-title":"Molecular mechanism of HIV-1 entry","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1422269112","article-title":"Stable,\u00a0uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure","volume":"111","author":"Kovacs","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0969-2126(00)00547-5","article-title":"Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted\u00a0and primary isolates","volume":"8","author":"Kwong","year":"2000","journal-title":"Structure"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2182743\/v1","article-title":"Computational modeling of virally-encoded ion channel structure","author":"Weissman","year":"2022","journal-title":"Res Sq"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.9.4186","article-title":"Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: target CD4 recognition and docking mechanism","volume":"90","author":"Gabriel","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1038\/s41586-024-07082-z","article-title":"Publisher Correction: Intermediate conformations of CD4-bound HIV-1 Env heterotrimers","volume":"626","author":"Dam","year":"2024","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0165110","DOI":"10.1371\/journal.pone.0165110","article-title":"An analysis of drug resistance among people living with HIV\/AIDS in Shanghai, China","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000720","article-title":"Gender Differences in Adverse Drug Reactions during HAART Therapy in HIV\/AIDS Patients at a Tertiary Care Hospital Penang, Malaysia","volume":"8","author":"Kashif Ullah","year":"2017","journal-title":"J AIDS Clin Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2174\/1568026615666150901114527","article-title":"Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41","volume":"16","author":"Lu","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00280-20","article-title":"The HIV-1 env gp120 inner domain shapes the phe43 cavity and the CD4 binding site","volume":"11","author":"Pr\u00e9vost","year":"2020","journal-title":"mBio"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02151-16","article-title":"Histidine 375 modulates CD4 binding in HIV-1 CRF01_AE envelope glycoproteins","volume":"91","author":"Zoubchenok","year":"2017","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/srep21759","article-title":"Arginine side chain interactions and the role of arginine as a gating charge carrier in voltage sensitive ion channels","volume":"6","author":"Armstrong","year":"2016","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1176","DOI":"10.1371\/journal.pone.0001176","article-title":"Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key","volume":"2","author":"Das","year":"2007","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/jp101909a","article-title":"Arginine-assisted solubilization system for drug substances: solubility experiment and simulation","volume":"114","author":"Hirano","year":"2010","journal-title":"J Phys Chem B"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199938","article-title":"Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1795238","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1648546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:41:22Z","timestamp":1771911682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1648546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1648546"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1648546","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1648546.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1648546.s002","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1648546"}}